secwatch.observer — SEC 8-K summary
======================================

Issuer:     OptimizeRx Corp (OPRX)
CIK:        0001448431
Form:       8-K
Filed at:   2024-11-13T23:59:59+00:00
Accession:  0001213900-24-097468
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OptimizeRx Q3 revenue $21.3M (+30% YoY); GAAP net loss $(9.1)M; guides FY24 rev $88-$92M
--------------------------------------------------------------------------------

- Q3 revenue $21.3M, up 30% YoY from $16.3M; gross profit $13.4M (+37%); margin 63%.
- GAAP net loss $(9.1)M ($(0.50)/share) vs $(2.9)M loss last year; non-GAAP net income $2.3M ($0.12/sh) vs $1.6M.
- Adjusted EBITDA $2.7M, up from $0.9M; cash and equivalents $16.1M; paid down $2M on term loan post-quarter.
- Updated FY2024 guidance: revenue $88-$92M, Adjusted EBITDA $8-$10M; won 5 DAAP deals in Q3.
- Net revenue retention 127% (rolling 12-month); top-20 pharma customers revenue per avg $2.8M vs $1.9M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1448431/000121390024097468/0001213900-24-097468-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1448431/000121390024097468/ea0221012-8k_optimize.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-097468

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer